Congratulations to CTT and MyDerm for being chosen as one of the finalists of this year's Anugerah Inovasi Negara. MeDerm will be exhibting in the finale stage, so stay tuned!
(taken from MOSTI FB page)
NAK TAHU APA ITU INOVASI? INGIN LIHAT IDEA HEBAT ANAK WATAN?
Saksikan para Finalis Anugerah Inovasi Negara 2016 (AIN 2016) mempamerkan idea-idea inovasi mereka di pentas akhir AIN 2016. Pelbagai aktiviti menarik turut disediakan antaranya #ScienceShow #SpaceTalk#DIYSatellite #NanoTalk #ScienceBusking #ExploScience
Jom kita ke Pameran Anugerah Inovasi Negara 2016 (AIN 2016), pada 17 & 18 Oktober 2016 di Aras Bawah Nu Sentral Kuala Lumpur.
Hadiah menarik disediakan. Datanglah beramai-ramai.
We will be appearing in Malaysia Hari ini (MHI), LIVE on TV3 to talk more about Ops Luka! Details: 8.30am, 4th October 2016, Tuesday.
Our CEO, Dr. Khairul Idzwan Baharin will be speaking in this event at 10am. Be sure to catch him if you're around!
AUTM Asia 2015 will be the largest gathering of academic research institutions, industry, technology transfer professionals and entrepreneurs in Asia. The four-day event will feature prominent speakers from North America, Asia, Australia and Malaysia discussing on the latest technology transfer trend. 10 reasons to head over to booth 40 and say HI!
1. Here’s your chance to experience a luxury treat at Starhill Gallery, Bukit Bintang (if you register now) and GRAB:
2. If you’re a biomedical researcher, in need for human primary cells – Come and talk to us. Variety of cells and special offers are waiting!
3. So you have a cosmetic line, skin or personal care products? Get them validated and tested on our human skin or cells, so you’ll have optimized formulation – out beat your competitors!
4. Perhaps you’re on skin related research? We can provide you with human skin, 3D skin or equivalents, monolayer or bilayer, fresh or cryopreserved, viable or non-viable; you name it, we custom-produce them for you!
5. Are you a patient or caregiver? Here’s your chance to enroll in our clinical/case studies and experience our range of advanced treatment at no cost while contributing to medical advancement!
6. Interested to learn more on how we do it? Register for our "GMP Workshop for Cell and Tissue Production” and secure your seats as they are limited (only 30 pax). First come first serve!
7. Free consultation with our dermatologist/clinic director (by appointment only) and product specialists on site!
8. Are you a doctor, surgeon, physician, aesthetician, beautician or medical researcher? Register you interest to refer your patients or incorporate our treatment in your treatment options, or even join our hands-on training so you’re one level higher from your peers!
9. Interested in Collaborating? Partnering? Distributing? Investing? Supplying? You got that right, head over here and get the ball rolling. We may strike a good deal!
10. Show us your support by getting to know us more, sign our guestbook and take a glimpse of what Malaysia’s very own home-grown Tissue Engineering Company has to offer!
See you there, peeps! Please contact Ms. Gargy / Mr Anwar:
+6012 719 8455 | +603 9545 3737 | www.celltissue.com.my | email@example.com
Cell Tissue Technology (CTT) proudly announces that the upcoming aesthetic product, CelltiF has made its way to the finals of GIST tech-I, 2014. Project manager, Gargy Lahiry has been selected as one of the 30 finalists from 67 semifinalists on this global competition, takes place every year. The finalists are entitled to attend 5th Global Entrepreneurship summit in Marrakech, Morocco, this November. As an integral part of the Global Entrepreneurship Summit (GES), the GIST TECH-I competition will be enriched with participants from Africa, Middle East and Asia. CCO, Dr. Heikal Yunus will be presenting CelltiF on this prestigious event, as a representative of CTT.
GIST TECH-I is a global competition to identify and support the most promising technology and science entrepreneurs. The GIST Initiative is led by the U.S. Department of State and CRDF Global. Tech-I is designed to encourage and support technology and science entrepreneurs to launch and/or grow a company in Africa, Asia, the Middle East, and Turkey through training and mentorship with successful entrepreneurs, angel investors, and venture capitalists.
The event will be enriched with the presence of important personnel from all over the world, including Ministers from Moroccan Foreign affairs, Economy and Finance, Trade and investment, along with the US secretary of Commerce, and top if it, the US vice president, Joe Biden.
This event is a big platform to facilitate the exchange of views and ideas between global business leaders and entrepreneurs and strengthen alliances among entrepreneurs around the world, and CTT had the glory to make it to the finals of this happening event 2 times since 2012.
We'll be at Global Entrepreneurship Summit 2013, KL Convention Centre, Kuala Lumpur. Catch MyDerm LIVE at the event!
Cell Tissue Technology Sdn Bhd (CTT) today announces its participation at the 2013 Biopharma Asia Convention held in Sentosa Island, Singapore from 18 – 21 March 2013.
The 2013 BioPharma Asia Convention is the largest and most strategic event in Asia that brings together more than 4,000 key stakeholders and decision makers from across the globe to explore partnership ideas, business trends and investment opportunities in Asia's bio-pharmaceutical sector.
This year's BioPharma Asia Convention was dedicated entirely to the value chain of the pharmaceutical industry, including innovations, technologies and methodologies in driving drug discovery development across Asia. The convention also explored the latest technology and best practices in increasing biologic manufacturing productivity, licensing and partnering opportunities in Asia, particularly in the fields of pharmaceutical and biotechnology. In addition, the conference also showcased the latest trends and development in Asia's top 3 diseases – cardiology, oncology and diabetes.
The CEO of Cell Tissue Technology Sdn Bhd, Dr Khairul Baharin gave two speeches at two different sessions of the Convention. The first speech entitled "Assessing Commercial Opportunities and Challenges for Stem Cell Applications In Asia” was delivered on 19 March 2013. The session also involved discussions on accessing the trends, opportunities and challenges in the commercialization of stem cell applications in Asia as a viable business model. There was an in-depth analysis of the capabilities of popular countries in Asia in commercializing stem cell applications for therapeutic and drug discovery purposes.
The second speech, titled "Formation of Autologous Bilayer Tissue Engineered Human Skin Using HPD as Biomaterials” was delivered on 20 March 2013. The session covered a demonstration of CTT's key product, MyDerm™. Among the areas touched were on MyDerm™'s unique characteristics, underlying principles of tissue engineered skin using HDP as biomaterials and identifying the needs of the study towards solving current and upcoming clinical problems. This is in addition to discussions on the efforts and initiatives to recognize and ascertain suitable alternatives to the current gold-standard treatments and the journey from the laboratories to bedsides.
The events helped the attendees to gain an insight into Asia' stem cell industry from leading pharmaceuticals, biotechnology companies and research institutes to identify and assess the critical issues at the interface of stem cells and regenerative medicine. These sessions also helped to uncover the latest breakthroughs in Asia's stem cell industry besides getting engaged in meaningful discussions with the industry's veterans and global heavyweights.
Such events are important and crucial to create prospects for business collaborations between basic research scientists and pharmaceutical companies.
Cell Tissue Technology Sdn Bhd announces today that the Company's key product, MyDerm™ is listed among the 50 Innovation Business Opportunities (IBO) at the 6th Governance Council Meeting of Agensi Inovasi Malaysia (AIM).
According to AIM, MyDerm™ has the potential to generate a revenue of RM3.07 million in 3 years' time.
IBO is a continuous project under AIM that showcases locally developed potential innovations that are available for bidding by individuals and companies locally and abroad. The emphasis is to secure a business partner to commercialize the intellectual properties of universities and research institutes in Malaysia.
AIM's role is to bridge and facilitate the processes involved by publishing on their website every quarter the 50 projects available for interested parties to "bid”. Bidding here does not refer to any monetary transactions but indicates an interest. When a party bids for a project, it is required to provide information to AIM for screening with the owners of the IPs.
An introductory meeting will be held between the bidder and the IP owner to discuss potential modes of cooperation or collaboration.
MyDerm™ was included with 49 other projects which were announced by the Prime Minister, Dato' Seri Najib Tun Razak.
Details for bidding are now available at www.innovation.my.
Cell Tissue Technology Sdn Bhd (CTT) is a Malaysian-based company established as a spin-off from the National University of Malaysia or UKM. One of the early ideas behind the formation is to manufacture and commercialize MyDerm™ - an autologous tissue engineered medical product researched and developed by the Tissue Engineering Centre of UKM.
Currently there are less than 10 companies in the country adopting advanced medical technology as their core business activities. Many are still wedged at the pre-commercialization stage and none has boasts any success story in the market. CTT aims to be at the forefront of Malaysia's advanced medical industry in areas of tissue engineering and regenerative medicine. Our first step towards this direction is our introduction of MyDerm™, the first tissue engineered human skin in Malaysia.
ABOUT MyDERM™ - THE JOURNEY
MyDerm™ is an advanced 3D autologous skin substitute meant for the repair of full thickness skin loss. This skin substitute is permanent, able to replace the traditional skin and have proven to enhance wound healing.
MyDerm™ is used mainly to replace skin loss due to burns, injuries, diseases and infections.
MyDerm™'s contribution to the medical scene is enormous and significant, more so for diabetic patients who generally suffer from poor wound healing. The prevention of infections to open wounds will reduce greatly the dreaded solution of amputation.
As such, CTT is confident that the introduction of MyDerm™ will revolutionize the local medical industry, bringing hope and solutions to people who need it – doctors, patients, surgeons, consultants, etc.
To ensure its effectiveness and safety, MyDerm™ will be extensively used clinically on patients. The research and development for this product was completed in big animal study and Limited Clinical Application in June 2008. The prototype also underwent several tests such as "Toxicology for Safety”, "Rejection on Implantation” and "Flowcytometry Cell Cycle Analysis”. There were no incidents of infections, graft losses, excessive bleeding or hematoma. Patients reported less pain, less scaring and discoloration after treatment.